$556 Million is the total value of Ghost Tree Capital, LLC's 128 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CPRX | Exit | CATALYST PHARM PARTNERS INC | $0 | – | -250,000 | -100.0% | -0.36% | – |
| WMGIZ | Exit | WRIGHT MED GROUP INCright 03/01/2019 | $0 | – | -185,000 | -100.0% | -0.42% | – |
| ASPX | Exit | AUSPEX PHARMACEUTICALS INC | $0 | – | -20,000 | -100.0% | -0.50% | – |
| SNN | Exit | SMITH & NEPHEW PLCspdn adr new | $0 | – | -30,000 | -100.0% | -0.53% | – |
| TNDM | Exit | TANDEM DIABETES CARE INC | $0 | – | -100,000 | -100.0% | -0.61% | – |
| RPTP | Exit | RAPTOR PHARMACEUTICAL CORP | $0 | – | -150,000 | -100.0% | -0.76% | – |
| BLCM | Exit | BELLICUM PHARMACEUTICALS INC | $0 | – | -75,000 | -100.0% | -0.83% | – |
| Exit | IMMUNOGEN INC | $0 | – | -300,000 | -100.0% | -0.88% | – | |
| ACHN | Exit | ACHILLION PHARMACEUTICALS INcall | $0 | – | -150,000 | -100.0% | -0.88% | – |
| ATRC | Exit | ATRICURE INC | $0 | – | -100,000 | -100.0% | -0.96% | – |
| ARIA | Exit | ARIAD PHARMACEUTICALS INC | $0 | – | -300,000 | -100.0% | -0.99% | – |
| BDSI | Exit | BIODELIVERY SCIENCES INTL IN | $0 | – | -175,000 | -100.0% | -1.01% | – |
| ISRG | Exit | INTUITIVE SURGICAL INC | $0 | – | -4,000 | -100.0% | -1.02% | – |
| ARAY | Exit | ACCURAY INC | $0 | – | -300,000 | -100.0% | -1.09% | – |
| VRX | Exit | VALEANT PHARMACEUTICALS INTL | $0 | – | -20,000 | -100.0% | -1.37% | – |
| QDEL | Exit | QUIDEL CORP | $0 | – | -100,000 | -100.0% | -1.39% | – |
| OPHT | Exit | OPHTHOTECH CORP | $0 | – | -65,000 | -100.0% | -1.40% | – |
| ISIS | Exit | ISIS PHARMACEUTICALS INCput | $0 | – | -50,000 | -100.0% | -1.48% | – |
| SYK | Exit | STRYKER CORP | $0 | – | -35,000 | -100.0% | -1.58% | – |
| UHS | Exit | UNIVERSAL HLTH SVCS INCcl b | $0 | – | -30,000 | -100.0% | -1.60% | – |
| AMAG | Exit | AMAG PHARMACEUTICALS INC | $0 | – | -80,000 | -100.0% | -1.64% | – |
| SLXP | Exit | SALIX PHARMACEUTICALS INC | $0 | – | -30,000 | -100.0% | -1.65% | – |
| KITE | Exit | KITE PHARMA INC | $0 | – | -60,000 | -100.0% | -1.66% | – |
| AIRM | Exit | AIR METHODS CORP | $0 | – | -85,000 | -100.0% | -1.80% | – |
| HZNP | Exit | HORIZON PHARMA PLC | $0 | – | -300,000 | -100.0% | -1.86% | – |
| INSYQ | Exit | INSYS THERAPEUTICS INC NEW | $0 | – | -100,000 | -100.0% | -2.02% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -115,000 | -100.0% | -2.13% | – |
| DEPO | Exit | DEPOMED INC | $0 | – | -300,000 | -100.0% | -2.32% | – |
| LJPC | Exit | LA JOLLA PHARMACEUTICAL CO | $0 | – | -286,053 | -100.0% | -2.53% | – |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -65,000 | -100.0% | -2.94% | – |
| ISIS | Exit | ISIS PHARMACEUTICALS INCcall | $0 | – | -150,000 | -100.0% | -4.44% | – |
| SYK | Exit | STRYKER CORPcall | $0 | – | -100,000 | -100.0% | -4.53% | – |
| GILD | Exit | GILEAD SCIENCES INCcall | $0 | – | -125,000 | -100.0% | -5.65% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 30 | Q3 2023 | 7.3% |
| ASCENDIS PHARMA A/S - ADR | 28 | Q3 2023 | 11.8% |
| BIOCRYST PHARMACEUTICALS INC | 25 | Q2 2023 | 2.4% |
| AMICUS THERAPEUTICS INC | 23 | Q3 2023 | 5.6% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2023 | 9.1% |
| SPDR SER TR | 20 | Q3 2022 | 16.9% |
| IOVANCE BIOTHERAPEUTICS INC | 18 | Q2 2023 | 5.5% |
| ROCKET PHARMACEUTICALS INC | 18 | Q2 2023 | 6.1% |
| SAGE THERAPEUTICS INC | 18 | Q1 2021 | 4.8% |
| IMMUNOMEDICS INC | 17 | Q2 2020 | 8.7% |
View Ghost Tree Capital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-16 |
| 13F-HR | 2021-11-15 |
View Ghost Tree Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.